A panel discussion about biotechnology

with Susan Desmond-Hellmann and Robert Klein
in Current Affairs, Science & Health, Business
on Thursday, November 18, 2004 * * * * *

Sorry, this video isn’t available at the moment; please check back soon.

play

E-mail this video:

Distribute this video:

Share on:

Close
Description

A panel discussion about biotechnology with Brook Byers of Kleiner, Perkins, Caufield & Byers, Susan Desmond-Hellmann MD, President of Product Development at Genentech, and Robert Klein, campaign chair for Proposition 71.

Video Share Options
Share
Buy Amazon DVD
Keywords:
Mountain View
TechNet summit
Genentech
California
Brook Byers
Proposition 71
internet
biotechnology
Robert Klein

In order to download Charlie Rose podcasts to iTunes for transfer to an iPod, you must have iTunes installed. If you do, please click the following link to download the podcast for this interview:

itpc://www.charlierose.com/view/itunes/1175

Otherwise, close this window to continue viewing.

Close
  • Comments 1
    Post new comment
    1. Amy1234567  03/10/2010 05:32 PM Report

      I agree with the idea of how clinical trails will be affected and certain things about the trials will change, like the size of the trials.With the underfunding at a federal level the therapy is more affected with toxic chemicals so when someone is told that they have cancer, they are not scared and instead of thinking right away that they are just going to die, they will be more confient to take the medicine that will treat the cancer and they will be all fine.